REG - Craneware plc - FY24 Trading Update and Notice of Results

CranewareAnnouncement

18/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240718:nRSR8453Wa&default-theme=true

RNS Number : 8453W  Craneware plc  18 July 2024

Craneware plc

 

("Craneware", the "Craneware Group", the "Company" or the "Group")

 

FY24 Trading Update and Notice of Results

 

18 July 2024 - Craneware (AIM: CRW.L), the market leader in Value Cycle
solutions for the US healthcare market, today provides an update on trading
for the year ended 30 June 2024 (FY24).

 

The Board is pleased to announce a positive year for the Group. The ongoing
investment in the Trisus platform has delivered a good sales performance in
the year and, combined with our partner programs, we have delivered
significant returns to the Group's US healthcare provider customer base. As a
result, revenue for the year is expected to exceed $188m which is above the
upper end of current market expectations, an 8% increase over the prior year
(FY23: $174.0m). The Group also expects to deliver an adjusted EBITDA of at
least $58m, a 6% increase over the prior year (FY23: $54.9m) and towards the
top end of market expectations, continuing its delivery of an above 30% EBITDA
margin.

 

This healthy sales performance and continued high levels of customer retention
have delivered growth in Annual Recurring Revenue(1) (ARR) to $172m (30 June
2023: $169m), with additional growth expected as more of the sales and partner
success convert to ARR.

 

Strong balance sheet and accelerated debt reduction

 

The Group's high levels of cash generation have allowed ongoing investment in
the future of the business while at the same time the Group has:

 ·             Reduced its total bank debt to $35.4m (FY23: $83m), a further $40m above its
               normal scheduled repayments
 ·             Returned $12.8m to shareholders (FY23: $12.1m) by way of dividends;
 ·             Completed c.$3.3m of share purchases through both the announced share buyback
               and purchase of shares by the Employee Benefit Trust.

The Group has also retained healthy cash reserves of $34.6m at 30 June 2024
(FY23: $78.5m).

 

Outlook

 

The strong sales performance during the year demonstrates the strength of the
Trisus platform, increasing partner success and the unique position the Group
holds in its market.

 

The breadth of solutions the Craneware Group can provide though its Trisus
platform, combined with the new market opportunities, accelerated innovation
and exploration of new AI-based applications that will result from the
recently announced alliance with Microsoft, give the Board confidence in the
Group's ability to provide the insights its customers need to deliver greater
value healthcare to their communities.

 

The Group's balance sheet strength, high levels of ARR and returns generated
for our customers, leave the Group well positioned for FY25 and beyond.

 

Notice of Results

 

Craneware will announce its results for the year ended 30 June 2024 on 3
September 2024.

 

Keith Neilson, CEO of Craneware plc, commented,

 

"The drive for better value in healthcare continues to dominate strategic
priorities within the US healthcare market. Our positive financial results
reflect the demonstrable impact the Craneware Group can make, in helping our
customers meet these priorities.

 

The exciting growth and expansion opportunities that our new alliance with
Microsoft brings to the Group, combined with our continued investment in the
Trisus platform, the considerable data assets we maintain, and our
independence within the US healthcare market mean we are uniquely placed to
support all US hospitals.

 

Supported by a strong balance sheet, high levels of revenue visibility and the
partnerships and alliances we are developing, we are confident this year's
healthy performance is evidence of the expanded and long-term opportunities
that are ahead of us."

 

 

Notes

 (1) Annual Recurring Revenue ("ARR") includes the annual value of licence
and transaction revenues as at 30 June 2024 that are subject to underlying
contracts and where revenue is being recognised.

 

 

For further information, please contact:

 

 Craneware plc                                    +44 (0)131 550 3100
 Keith Neilson, CEO
 Craig Preston, CFO

 Alma Strategic Communications (Financial PR)     +44 (0)20 3405 0205
 Caroline Forde, Joe Pederzolli, Kinvara Verdon   craneware@almastrategic.com

 Peel Hunt (NOMAD and Joint Broker)               +44 (0)20 7418 8900
 Neil Patel, Benjamin Cryer, Kate Bannatyne

 Investec Bank PLC (Joint Broker)                 +44 (0)20 7597 5970
 Patrick Robb, Henry Reast, Shalin Bhamra

 Berenberg (Joint Broker)                         +44 (0)20 3207 7800
 Mark Whitmore, Richard Andrews, Dan Gee-Summons

 

 

About Craneware

 

The Craneware Group (AIM:CRW.L), is the market leader in value cycle
solutions. For 25 years, we have collaborated with U.S. healthcare providers
to optimize revenue integrity, pricing intelligence, decision support, labor
productivity, business of pharmacy, and 340B program management. 

 

Customers choose Trisus®, a HITRUST- and SOC2 Type II-certified,
SaaS-platform, to achieve operational and financial excellence in pursuit of
their healthcare mission - delivering quality care to their communities. The
Craneware Group - Transforming the Business of Healthcare.

 

Learn more at www.craneware.com (http://www.craneware.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFDLLFZDLLBBZ